THC TENET HEALTHCARE CORP Insider Trading

EVP/CIO Paola M Arbour sold 6,500 THC shares at $238.43 on 2026-03-11 ($1.5M); holds 29.3K shares remaining.

Arbour sold 6,500 shares (a reduction of 18.2% from pre-transaction holdings of 35.8K shares) at $238.43, which was 4.7% above the current price of $227.63 and near the 52-week high of $244.80. At the 90-day mark, her prior five sales at this ticker have produced an average return of +9.6%, with 0 of 5 showing negative returns—indicating she has historically sold ahead of appreciation rather than ahead of declines. Her cross-ticker track record shows 0.00% well-timed rate on 6 prior sells (avg 90d return +10.4%), suggesting limited predictive timing skill overall. The company trades at a P/E of 33.09 with recent quarterly revenue of $5.3B and net income of $579.0M (annual growth +3.1%), fundamentals that do not signal distress. The transaction appears discretionary and falls within routine insider rebalancing of a large holding.

EVP/CAO Arnst Thomas W sold 8,000 shares (99.9% of holdings) at $238.85 avg for $1.9M on 2026-03-09.

Arnst Thomas W, EVP, Chief Administrative Officer and General Counsel, executed 2 separate sales totaling 8,000 shares for $1,910,777.44, leaving only 12 shares post-transaction. The blended average transaction price of $238.85 is near the current price of $237.42 and within recent trading range context (52-week high $244.80). Across his prior 4 measurable sales at THC, 0 of 4 were well-timed at the 90-day mark, meaning the stock rose after each prior sale; his 90-day average return post-sale at THC was +20.4%, suggesting a pattern of selling ahead of appreciating periods. The near-complete portfolio exit by a C-suite legal and administrative officer differs materially from his smaller prior sales at this ticker and warrants investor attention to accompanying circumstances (severance, resignation, planned departure, or personal portfolio realignment).

EVP Thomas Arnst sold 24,000 THC shares at $234.04 on 2026-03-02; stock now at $242.88 (+0.0% from 52-week high)

Arnst, the Chief Admin Officer and General Counsel, divested 75.0% of his holdings (24,000 shares, $5.6M) at $234.04, retaining 8,012 shares post-transaction. The sale occurred near the 52-week high of $242.88, with the stock up 28.3% over the prior 30 days and 14.9% over 90 days. His prior trades at THC have been poorly timed overall: of 5 prior sales at this ticker, only 1 was well-timed (negative 90-day return), while the other 4 were followed by positive returns ranging from +7.2% to +41.6%, indicating he typically sold before upside materialized. His cross-ticker track record shows a 33.33% well-timed rate across 6 prior sells, which is below a 50% baseline and suggests inconsistent timing discipline. The fundamental backdrop—$5.3B quarterly revenue, +3.1% annual growth, and a P/E of 35.30—reflects a mature healthcare operator trading at a premium valuation; the executive's near-complete exit warrants observation given the recent momentum and his historically reactive sell pattern.

Principal Accounting Officer Ramsey R. Scott sells all 8,017 shares (100% of holdings) for $1,865,576.86

Ramsey R. Scott, Principal Accounting Officer at Tenet Healthcare (THC), executed 3 separate sales on 2026-03-02, liquidating his entire 8,017-share position for $1,865,576.86 at a blended average price of $232.70. This complete exit is material in scale and represents the elimination of the insider's equity stake in the company. Scott's trading pattern at THC over 4 prior transactions shows a 100% well-timed rate at the 90-day mark, with all prior sales followed by stock declines (ranging from -6.9% to -12.7% over 90 days); however, the current stock price of $242.88 is at the 52-week high (+0.0% from peak) and has surged +28.3% in the past 30 days, creating a significant divergence from the insider's execution price and recent momentum trajectory. The complete liquidation of holdings by a senior financial officer merits scrutiny, as it may signal confidence in near-term pricing or liquidity needs, though the current elevated valuation and positive price momentum make the broader investment thesis context relevant to investors assessing this signal.

Principal Accounting Officer Ramsey R. Scott sells entire 13,322-share stake in Tenet Healthcare (THC) for $2.7M; blended average $205.11 near current price of $205.26

Ramsey R. Scott completed a complete exit of his THC position via 3 separate sales totaling 13,322 shares for $2,732,438.92, reducing holdings from 13,322 shares to 0 shares (-100.0%). The transactions executed at prices ranging from $204.75 to $206.51, with a blended average of $205.11, approximately at the current market price of $205.26. Across his entire insider trading history spanning multiple tickers, Scott has completed 1 prior sell that achieved a 100.00% well-timed rate at the 90-day mark, with that same THC sale on 2024-09-05 delivering -12.7% return over 90 days. While the stock is currently -5.0% from its 52-week high and has posted +24.0% over 90 days, the complete liquidation by the Principal Accounting Officer warrants investor attention as a material change in insider position.

Director Romo Tammy sold 26,855 shares ($5.4M) at $202.23 avg price; -43.1% of holdings.

Romo Tammy, a Director at Tenet Healthcare, executed 5 separate sales totaling 26,855 shares for $5,430,970.75 over two trading days (November 3–4, 2025) at an average price of $202.23 per share, reducing her holdings by 43.1% from 62,366 to 35,511 shares. The scale of this reduction—nearly half of prior holdings liquidated within 48 hours—represents a material realignment of her equity position in the company. At the transaction prices of $200.43 to $204.93, the sales occurred 1.6% to 2.1% below the current price of $208.62, and the stock has appreciated 27.7% over the past 90 days and 4.4% over the past 30 days, indicating upward momentum at the time of sale. The relatively low valuation (P/E of 7.99 despite $5.3B in quarterly revenue and $579.0M net income) provides context for evaluating this large reduction in executive exposure.

CEO Sutaria Saumya sold 78,762 shares at avg $190.78 on 2025-09-10 for $15.0M, reducing holdings by 17.6%.

Saumya conducted 2 separate sales totaling 78,762 shares (78.8K shares) for $15,026,139.08 ($15.0M), executed at blended average price of $190.78 per share. The sale reduces her post-transaction holdings to 368,683 shares (368.7K shares), representing a 17.6% reduction from pre-transaction holdings of 447,445 shares (447.4K shares). At the ticker-specific level, her prior 4 trades at THC show a 0% well-timed rate at the 90-day mark, with returns following those sales ranging from +4.5% to +5.7%, suggesting her past sales preceded gains rather than declines. Current market conditions show THC trading at $192.82, only -1.8% from its 52-week high of $196.39, with strong recent momentum (+12.2% over 30 days, +17.3% over 90 days), creating context for this large liquidation near recent highs.

COO Foo Lisa Y sold 8,000 THC shares at $179.53 (8.0K shares, $1.4M); holdings reduced 27.7%

Foo Lisa Y, EVP and Chief Operating Officer, sold 8,000 shares at $179.53, reducing her total holdings from 28,878 to 20,878 shares—a reduction of 27.7% of her pre-transaction position. The sale occurred near the stock's 52-week high of $181.94 (just 1.3% below peak), following a 13.4% gain over 30 days and 10.1% over 90 days. Tenet Healthcare's fundamentals remain modest: the company generated $5.3B in revenue with $522.0M net income in the latest quarter, yet trades at a low P/E of 6.62 with annual revenue growth of only +0.6%, suggesting limited organic momentum. The COO's material reduction in equity stakes merits monitoring to determine whether this reflects broader executive positioning or personal capital allocation decisions.

Paola M Arbour (EVP/CIO) sells 7,738 shares of THC at $173.00; holds 20,110 shares post-transaction.

Arbour sold 7,738 shares (27.8% of pre-transaction holdings) at $173.00 on 2025-06-05, reducing her stake to 20,110 shares. The sale occurred at a price only 0.2% below the 52-week high of $171.84, and the stock has advanced 12.6% over the prior 30 days and 34.5% over 90 days. Her prior 4 measurable sells at THC all returned positive 90-day gains (ranging +2.8% to +36.4%), suggesting a pattern of selling into strength rather than ahead of declines; none of those four prior sales was well-timed in the directional sense. Given the stock's strong recent momentum and valuation metrics (P/E 6.77, market cap $15.9B), this sale represents a reduction of position concentration following a sustained rally rather than a signal of deterioration.

Director James L Bierman sold 13,836 shares (−25.0% of holdings) at $159.35–$160.00 on 2025-05-23 for $2.2M.

James L Bierman, a director of Tenet Healthcare, executed two separate sales on 2025-05-23, reducing his holdings from 55,271 shares to 41,435 shares. The sales totaled 13,836 shares at a blended average price of $159.58, generating $2,208,016.60. The company's current stock price is $165.10, above the transaction prices and near its 52-week high of $168.66. With a P/E of 6.52 and quarterly revenue of $5,223,000,000.00, Tenet trades at relatively modest multiples. The sale represents a material reduction in Bierman's personal stake but occurs in a context of strong recent price momentum (30-day change: +35.2%; 90-day change: +25.3%), making the timing of this divestiture a point for investors to consider.